Harrow (NASDAQ:HROW) Earns “Buy” Rating from HC Wainwright

Harrow (NASDAQ:HROW)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $57.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 128.18% from the company’s previous close.

Separately, B. Riley reduced their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

Harrow Stock Performance

Shares of Harrow stock opened at $24.98 on Monday. The stock’s fifty day simple moving average is $28.53 and its 200 day simple moving average is $37.72. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The company has a market capitalization of $889.66 million, a PE ratio of -26.57 and a beta of 0.69. Harrow has a 12 month low of $9.86 and a 12 month high of $59.23.

Harrow (NASDAQ:HROW) last released its quarterly earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The company had revenue of $66.83 million for the quarter, compared to analyst estimates of $66.01 million. On average, research analysts predict that Harrow will post -0.53 EPS for the current year.

Institutional Investors Weigh In On Harrow

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after acquiring an additional 194,480 shares in the last quarter. Barclays PLC boosted its holdings in Harrow by 301.9% during the third quarter. Barclays PLC now owns 52,593 shares of the company’s stock worth $2,365,000 after purchasing an additional 39,506 shares during the last quarter. State Street Corp boosted its holdings in Harrow by 2.2% during the third quarter. State Street Corp now owns 730,973 shares of the company’s stock worth $32,865,000 after purchasing an additional 15,554 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after purchasing an additional 166,602 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Harrow in the 3rd quarter valued at $1,469,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.